High-Dose Ascorbic Acid
High Dose Ascorbic Acid for Plasma Cell Disorders
What will happen during the trial?
This is a phase 1 study for patients with relapsed refractory multiple myeloma. Patients will receive a 15-gram test dose, and a maximum of 3 cycles, each composed of 4 doses of high-dose ascorbic acid (HDAA) and 2 doses of melphalan. This study will enroll 9 patients with relapsed refractory multiple myeloma. The starting dose of ascorbic acid will be 50 grams. Using a 3+3 dose escalation, the dose will potentially increase to 75 grams then 100 grams.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 9 patients (estimated)
- Sponsors
- Holden Comprehensive Cancer Center - University of Iowa
- Tags
- Chemotherapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 992
- NCT Identifier
- NCT03602235
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.